IGF1R and neoplasm: The fact that IGF1R hyper-activation, which has also been identified as an ERK-independent mechanism, involves other signalling pathways such as PI3K/AKT suggests that the co-targeting of IGF1R/PI3K and MEK may be considered as a promising therapy to restore apoptotic response in ERK-independent resistant tumours [84].